Replies to post #594988 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

I don't know. For the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS higher than 1, the recommended dose of KEYTRUDA is either 200 mg every 3 weeks or 400 mg every 6 weeks administered as an intravenous infusion over 30 minutes.